{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:55:25Z","timestamp":1760622925412},"reference-count":40,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.cca.2014.01.005","type":"journal-article","created":{"date-parts":[[2014,2,5]],"date-time":"2014-02-05T13:43:07Z","timestamp":1391607787000},"page":"9-14","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Establishment of an ELISA to detect anti-glycyl-tRNA synthetase antibody (anti-EJ), a serological marker of dermatomyositis\/polymyositis and interstitial lung disease"],"prefix":"10.1016","volume":"431","author":[{"given":"Hiroaki","family":"Hane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinao","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumitsu","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2014.01.005_bb0005","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/BOR.0b013e328358bd85","article-title":"Myositis autoantibodies","volume":"24","author":"Casciola-Rosen","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cca.2014.01.005_bb0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11926-011-0176-8","article-title":"Antisynthetase syndrome","volume":"13","author":"Katzap","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.cca.2014.01.005_bb0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/art.1780350415","article-title":"Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease","volume":"35","author":"Hirakata","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2014.01.005_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jbspin.2009.08.008","article-title":"Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients","volume":"77","author":"Vancsa","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.cca.2014.01.005_bb0025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cca.2014.01.005_bb0030","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2014.01.005_bb0035","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2014.01.005_bb0040","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/emmm.201100626","article-title":"Aminoacyl-tRNA synthetases in medicine and disease","volume":"5","author":"Yao","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cca.2014.01.005_bb0045","doi-asserted-by":"crossref","first-page":"e60442","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2014.01.005_bb0050","doi-asserted-by":"crossref","first-page":"369432","DOI":"10.1155\/2012\/369432","article-title":"The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy","volume":"2012","author":"De Paepe","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.cca.2014.01.005_bb0055","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cca.2014.01.005_bb0060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2014.01.005_bb0065","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2014.01.005_bb0070","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cca.2014.01.005_bb0075","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2014.01.005_bb0080","series-title":"Labour and welfare of Japan (Japanese)","article-title":"The classification of pathogenesis and the development of therapy in systemic sclerosis: the classification of severity and the guideline for treatment. A research project for systemic sclerosis supported by the Ministry of Health","author":"Takehara","year":"2004"},{"key":"10.1016\/j.cca.2014.01.005_bb0085","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cca.2014.01.005_bb0090","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/s10165-004-0338-x","article-title":"Revised Japanese criteria for Sj\u00f6gren's syndrome (1999): availability and validity","volume":"14","author":"Fujibayashi","year":"2004","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cca.2014.01.005_bb0095","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3899\/jrheum.080726","article-title":"CENP-O, a protein localized at the centromere throughout the cell cycle, is a novel target antigen in systemic sclerosis","volume":"36","author":"Saito","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cca.2014.01.005_bb0100","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.20096","article-title":"Anti-DFS70 antibodies in 597 healthy hospital workers","volume":"50","author":"Watanabe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2014.01.005_bb0105","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/rheumatology\/kes073","article-title":"Clinical features of anti-TIF1-\u03b1 antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-\u03b3 or anti-Mi-2 autoantibodies","volume":"51","author":"Muro","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2014.01.005_bb0110","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/rheumatology\/kes033","article-title":"Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2","volume":"51","author":"Ishikawa","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2014.01.005_bb0115","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.cca.2014.01.005_bb0120","first-page":"137","article-title":"Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay","volume":"12","author":"Op De Beeck","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cca.2014.01.005_bb0125","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/jcp.2010.084756","article-title":"Sensitivity of the Phadia EliA connective tissue disease screen for less common disease-specific autoantibodies","volume":"64","author":"Parker","year":"2011","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.cca.2014.01.005_bb0130","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","article-title":"Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy","volume":"56","author":"Stone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2014.01.005_bb0135","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.21883","article-title":"Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis\/dermatomyositis","volume":"54","author":"Yamasaki","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2014.01.005_bb0140","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11926-013-0335-1","article-title":"Autoantibodies in polymyositis and dermatomyositis","volume":"15","author":"Ghirardello","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.cca.2014.01.005_bb0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"key":"10.1016\/j.cca.2014.01.005_bb0150","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2014.01.005_bb0155","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2014.01.005_bb0160","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2014.01.005_bb0165","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/archderm.144.10.1341","article-title":"Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling","volume":"144","author":"Somani","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cca.2014.01.005_bb0170","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jbspin.2010.07.012","article-title":"Anti-PL7 antisynthetase syndrome under interferon therapy","volume":"78","author":"Aouba","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.cca.2014.01.005_bb0175","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.cca.2014.01.005_bb0180","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.24977","article-title":"Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle","volume":"60","author":"Mammen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2014.01.005_bb0185","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/ar4131","article-title":"MicroRNA control in the development of systemic autoimmunity","volume":"15","author":"Hu","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cca.2014.01.005_bb0190","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2014.08.019","article-title":"The role of miRNA in inflammation and autoimmunity","volume":"12","author":"Singh","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cca.2014.01.005_bb0195","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/annrheumdis-2012-201654","article-title":"MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes","volume":"72","author":"Philippe","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cca.2014.01.005_bb0200","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4049\/jimmunol.1102348","article-title":"TLR2 expression is regulated by microRNA miR-19 in rheumatoid fibroblast-like synoviocytes","volume":"188","author":"Philippe","year":"2012","journal-title":"J Immunol"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T06:29:07Z","timestamp":1565159347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898114000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":40,"alternative-id":["S0009898114000229"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2014.01.005","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishment of an ELISA to detect anti-glycyl-tRNA synthetase antibody (anti-EJ), a serological marker of dermatomyositis\/polymyositis and interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2014.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}